Vorasidenib
Voranigo
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84
Voranigo (vorasidenib) USPI, DailyMed setid 31405fee-55b7-4857-987e-2724ee76be84 (version 9, 06.20.2026), label text re-used from the 10.27.2026 pull: sections 1, 2, 5.1, 6.1, 14 (INDIGO NCT04164901)
Brief source I1
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/37272516/
Mellinghoff IK et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO). N Engl J Med 2023;389:589-601. PMID 37272516 (abstract, carried from 10.27.2026 brief source G18)
Brief source I2
company_release, as of 2026-11-07
https://servier.mediaroom.com/
Servier release 05.31.2026, INDIGO extended follow-up at ASCO 2026 (company release; carried from G19)
Brief source I3
company_release, as of 2026-11-07
Servier release 11.06.2026: nine abstracts, five orals at SNO 2026 (11.12 to 11.15.2026, Philadelphia), incl. INDIGO 41.6-month follow-up, seizure and QoL analysis, real-world TTNI in 499 grade 2 patients and an 80-patient grade 3 cohort (company release)
Brief source I4
publication, as of 2026-11-07
https://aacrjournals.org/clincancerres/article/27/16/4491/671595/
Mellinghoff IK et al. Vorasidenib Phase 1 in recurrent or progressive glioma. Clin Cancer Res 2021;27:4491-4499 (abstract via search record)
Brief source I12
publication, as of 2026-11-07
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS2103
Alliance A072301 (VORTEX) design, J Clin Oncol 44(16_suppl) TPS2103, ASCO 2026; ClinicalTrials.gov NCT07215910
Brief source I17
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT04164901
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07215910
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06809322
Vorasidenib as Maintenance Treatment After First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma: a Placebo-controlled, Triple-blind, Randomized Phase III Study (VIGOR)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06780930
A Phase 3, Multicenter, Randomized, Double-blind, Placebo- Controlled Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06478212
A Phase 1b/2, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2-mutant Glioma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05484622
A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive IDH-1 Mutant Glioma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05609994
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07629089
VALIENT: Phase 1 Clinical Trial of VorAsidenib in Combination With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations
ClinicalTrials.gov API v2 record, retrieved 2026-11-07